Adipocytokines as a Novel Target for the Anti-inflammatory Effect of Atorvastatin in Patients With Type 2 Diabetes

  1. Maximilian von Eynatten, MD,
  2. Jochen G. Schneider, MD,
  3. Senad Hadziselimovic, MD,
  4. Andreas Hamann, MD,
  5. Angelika Bierhaus, PHD,
  6. Peter P. Nawroth, MD and
  7. Klaus A. Dugi, MD
  1. From the Department of Endocrinology and Metabolism, Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany
  1. Address correspondence to Maximilian von Eynatten, Department of Medicine I, University of Heidelberg, INF 410, D-69120 Heidelberg, Germany. E-mail: maximilian.eynatten{at}med.uni-heidelberg.de

Recently, Shetty et al. (1) reported a positive correlation of resistin with C-reactive protein (CRP) in a cross-sectional study of patients with type 1 or type 2 diabetes and patients in a pre-diabetic state. Collectively, however, little is known about the role of proinflammatory adipocytokines. The adipocyte-secreted hormones leptin and resistin have recently been regarded as pro-inflammatory cytokines positively associated with CRP in healthy subjects (2) and patients with diabetes (1). Shetty et al. therefore investigated whether atorvastatin may mediate part of its beneficial effects by altering resistin levels. They did find a 20% reduction of plasma resistin after statin treatment. Due to a concomitant decrease in the placebo group, however, …

| Table of Contents